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Inhibition of Pemphigus Vulgaris by 
Targeting of the CD40–CD154 Co-
Stimulatory Pathway: A Step Toward 
Antigen-Specific Therapy?
Zhi Liu1,2, Ning Li1 and Luis A. Diaz1
The signaling of CD40 by its ligand, CD154, between T and B cells is required 
for humoral immune responses. Thus, blockade of this ligand-receptor interac-
tion can prevent the development of antibody-mediated autoimmune diseases 
through different mechanisms.
Journal of Investigative Dermatology (2006) 126, 11–13. doi:10.1038/sj.jid.5700059
In autoantibody-mediated diseases, 
autoantigen-specific responses are 
induced by the activation of specific 
T cells with self-peptides displayed 
on antigen-presenting cells (APCs), 
including B cells, macrophages, and 
dendritic cells. These autoreactive T 
cells then activate and drive autoreac-
tive B-cell responses, leading to patho-
genic antibody production and subse-
quent disease development. The acti-
vation of naive T cells requires at least 
two signals. The first signal is delivered 
through interaction between the TCR 
and autoantigen associated with major 
histocompatibility complex molecules 
on the surface of the APCs. The sec-
ond signal is delivered through inter-
action of co-stimulatory molecules on 
the cell surface of T cells and APCs. 
Two co-stimulatory pathways, CD28–
CD80/CD86 and CD40–CD154, 
have received the most attention in 
this regard. CD28 is constitutively 
expressed on CD4+ T cells and binds to 
two different ligands, B7-1 (also called 
CD80) and B7-2 (also called CD86), 
which are expressed on APCs. CD154 
(also called CD40 ligand) is expressed 
mainly on CD4+ T cells, and CD40, 
the receptor for CD154, is expressed 
on APCs (Grewal and Flavell, 1998). 
If signal one is received without co-
stimulation (signal two), then the 
T cells undergo apoptotic death, and 
antigen-specific anergy is created. In 
contrast, if both signal one and signal 
two are received, the T cell undergoes 
upregulation of soluble factors, such 
as IL-2, which in turn permits expan-
sion of mature effector cells (T cells, 
B cells, and macrophages) to sustain 
immune responses.
CD40 ligation induces or increases 
expression of accessory molecules 
such as CD80, CD86, and major his-
tocompatibility complex II on the APC 
population. Thus, this pathway increas-
es both signals one and two. CD40–
CD154 interactions are critical for a 
variety of immune functions, including 
CD4+ and CD8+ T-cell priming, APC 
activation, antibody production, effec-
tor-cell maturation, and enhancement 
of inflammation and chemoattraction. 
A role for CD40–CD154 interactions 
in many organ-specific T cell-mediated 
autoimmune diseases, including col-
lagen-induced arthritis, experimental 
autoimmune encephalomyelitis, lupus 
nephritis, colitis, and diabetes, has 
been demonstrated in mouse models. 
Treatment of mice with anti-CD154 
antibody blocks disease in these mod-
els. Blockade of CD40–CD154 inter-
action is also beneficial in prolonging 
the survival of experimentally trans-
planted organs, including heart, kid-
ney, skin, and pancreatic islets (Sayegh 
and Turka, 1998).
Numerous mechanisms of the pro-
tective activity of CD40–CD154 inter-
vention in these autoimmune diseases 
have been proposed, including inhibi-
tion of autoreactive T-cell priming via 
T cell–APC interference; inhibition of 
the function, expansion and migration 
of effector T cells; immune deviation 
by cytokine blockade; induction of 
anergy; and elicitation of regulatory 
cells. These regulatory cells are T lym-
phocytes (known as regulatory T cells)  
that actively suppress or downregu-
late immune responses to maintain 
immune homeostasis (von Herrath and 
Harrison, 2003). Regulatory T cells 
can be induced by immunization with 
a self-antigen (for example, oral toler-
ance) and by treatment with antibodies 
specific for various T-cell molecules, 
including CD3, CD45RB, and CD154 
(Waldmann, 2002).
Pemphigus vulgaris (PV) is a life-
threatening autoimmune blistering 
disease. Clinically, PV targets the skin 
and mucosal epithelia. Histologically, 
PV is characterized by detachment of 
suprabasal keratinocytes (suprabasal 
acantholysis), leaving a row of basal 
keratinocytes attached to the dermis, 
which produces a “tombstone-like” 
appearance. PV patients have circulat-
ing autoantibodies that recognize des-
moglein-3 (Dsg3). Dsg3 is a 130-kilo-
dalton desmosomal glycoprotein that 
belongs to the desmoglein subfamily of 
the cadherin superfamily (Stanley et al., 
1982), a class of molecules that play an 
important role in mediating cell–cell 
adhesion. Anti-Dsg3 autoantibodies are 
pathogenic, as determined by passive 
transfer studies in which IgG isolated 
from sera of pemphigus patients, when 
injected into neonatal mice, induced 
acantholysis with the classic immu-
nohistological features seen in human 
patients (Anhalt et al., 1982).
The pathogenic relevance of Dsg3 
is further demonstrated by an active-
disease model of PV. In this PV mouse 
model, Dsg3 knockout (Dsg3–/–) mice 
are immunized with mouse Dsg3, 
and splenocytes from the immunized 
Dsg3–/– mice are adoptively trans-
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ferred to Rag2–/– mice. The recipient 
mice produce high levels of anti-Dsg3 
autoantibodies in circulation and a PV 
disease phenotype, including patchy 
hair loss and suprabasilar acantholy-
sis in oral mucosa and esophagus 
(Amagai et al., 2000). Rag2–/– mice 
receiving naive Dsg3–/– splenocytes 
also develop PV.
PV is associated with specific HLA 
class II alleles, including DRB1*0402, 
DRB1*1401, DQB1*0302, and 
DQB1*0503. Dsg3-reactive Th2 cells 
are present at elevated frequency in the 
peripheral circulation of PV patients 
compared with healthy control sub-
jects (Hertl and Veldman, 2003). 
Depletion of CD4+ T cells from the 
peripheral lymphocytes of PV patients 
blocks the production of anti-Dsg3 
antibodies by autoreactive B cells 
after in vitro stimulation with Dsg3. 
These findings suggest that autoreac-
tive T cells are crucial for induction 
and regulation of autoreactive B cells 
and production of anti-Dsg3 autoan-
tibodies. Very recently, Veldman et al. 
identified Dsg3-reactive regulatory 
T cells in healthy carriers of 
DRB1*0402 and DQB1*0503 alleles. 
These regulatory T cells secrete IL-10 
and suppress the immune response 
of Dsg3-reactive T helper cells in an 
antigen-specific manner that is depen-
dent on the cytokines IL-10 and trans-
forming growth factor-β; this suggests 
that Dsg3-specific regulatory T cells 
may be crucial in the maintenance of 
tolerance against Dsg3 autoantigen 
(Veldman et al., 2004).
In this issue, Aoki-Ota et al. report 
using a PV mouse model to investigate 
the role of CD40–CD154 interaction 
in the generation of pathogenic anti-
bodies and to understand the mecha-
nism of CD40–CD154 blockade in 
protection against PV development 
(Aoki-Ota et al., 2006). To address the 
first question, the authors administered 
anti-CD154 mAb into Rag2–/– recipient 
mice before adoptive transfer of sple-
nocytes from Dsg3-immunized Dsg3–
/– mice. Anti-CD154 antibody treat-
ment abolished PV blister formation; 
this was associated with a reduction 
in the levels of B cells producing anti-
Dsg3 IgG and the levels of anti-Dsg3 
antibodies. More significantly, the 
anti-CD154 mAb-induced tolerance 
to Dsg3 (as evidenced by the lack of 
pathogenic antibody production) was 
not transient and long lasting without 
continuous treatment. It is worth not-
ing that the authors should test whether 
anti-CD154 mAb pretreatment blocks 
PV in Rag2–/– mice adoptively trans-
ferred with naive Dsg3–/– splenocytes, 
as the immunized Dsg3–/– splenocytes 
used are already challenged with anti-
gen; therefore, naive Dsg3–/– spleno-
cytes may respond to the anti-CD154 
mAb differently from immunized 
Dsg3–/– splenocytes.
To elucidate the mechanism of pro-
tection, the authors tested whether reg-
ulatory cells might be involved. They 
first showed that once the immunized 
Dsg3–/– splenocytes transferred into 
Rag2–/– mice became resistant to PV 
by anti-CD154 mAb pretreatment, the 
protection could not be reversed by a 
second transfer of immunized Dsg3–/– 
splenocytes. Then, they demonstrated 
that PV resistance could be transferred 
from protected donors to non-toler-
ized recipients: Rag2–/– mice receiving 
naive Dsg3–/– splenocytes developed 
PV, whereas Rag2–/– mice receiving the 
same number of naive Dsg3–/– sple-
nocytes plus tolerized splenocytes 
from the anti-CD154 mAb-pretreated 
and immunized Dsg3–/– splenocyte-
transferred mice did not develop PV. 
These data strongly suggest that the 
CD40–CD154 blockade induces toler-
ance to Dsg3 by induction of regula-
tory cells capable of downregulation 
of immune responses to Dsg3. This key 
conclusion is further sustained by the 
authors’ demonstration that protected 
mice were still unresponsive to Dsg3 
after being rechallenged by active 
Dsg3 immunization. 
Another interesting finding of 
this study is that blockade of CD40–
CD154 interaction has only marginal 
therapeutic effects in the treatment of 
established PV. Similar observations 
have also been made in other models 
of autoimmune diseases. These find-
ings indicate that fully activated anti-
gen-specific B cells maintain their 
functions (for example, production 
of pathogenic autoantibodies) in a 
T cell-independent  and co-stimulatory 
signal-independent fashion. Therefore, 
efficacy of this therapeutic paradigm 
would depend on the disease stages 
of patients. Therapies based on induc-
tion of protective regulatory T cells 
would be more effective in preclinical 
disease. A critical question is whether 
anti-CD154 mAb will induce immune 
regulatory cells in PV mice that are 
in remission and prevent them from 
future disease relapse.
The role of the CD40–CD154 path-
way and the effects of CD40–CD154 
intervention have been extensively 
studied in animal models of differ-
ent autoimmune diseases. Aoki-Ota 
et al. now provide evidence that the 
CD40–CD154 interaction is essen-
tial for activation and expansion of 
Dsg3-specific B cells in the spleno-
cyte transfer model of PV. Blockade 
of CD40–CD154 signaling leads to 
induction or an increased level of 
immune regulatory T cells, which are 
able to suppress Dsg3-specific B-cell 
functions and subsequent disease 
development. Further investigation is 
necessary to isolate and characterize 
the nature and functions of such anti-
CD154 mAb-induced regulatory cells. 
This should allow confirmation of the 
tolerance-inducing potential of anti-
CD154 mAb and induced regulatory 
cells and lead to a better understand-
ing of the mechanisms involved, and 
it may be an important step toward an 
antigen-specific therapy for PV.
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UVA-Irradiated Pheomelanin Alters 
the Structure of Catalase and 
Decreases Its Activity in Human Skin
John M. Wood1 and Karin U. Schallreuter1,2
More than 40 years ago Aronoff showed that catalase structure and activity is 
seriously affected by photo-oxidation of its own substrate, hydrogen peroxide, 
owing to cleavage of its porphyrin active site. Here we support the results of 
Maresca et al. (in this issue) and expand on them by using structural modeling 
of native catalase and its photo-oxidation product, where both methionine and 
tryptophan residues are oxidized, yielding a deactivated enzyme.
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In this issue of the Journal of Investigative 
Dermatology, Maresca and co-workers 
show that both the charge and the activ-
ity of epidermal catalase are severely 
affected by reactive oxygen species 
(ROS) generated by UVA-irradiated 
pheomelanin photochemistry (Maresca 
et al., 2006, this issue). This work sup-
ports and expands on earlier research 
from Aronoff, who was the first to dem-
onstrate that the porphyrin ring of the 
active center of catalase is photo-oxi-
dized by UVR (Aronoff, 1965). Almost 
two decades later, Menon and col-
leagues showed that UV as well as vis-
ible light, together with pheomelanin, 
produced sufficient ROS, which in turn 
caused cytotoxicity of Ehrlich ascites 
carcinoma cells (Menon et al., 1983). 
Nowadays the production of short-lived 
singlet oxygen and its conversion to 
hydroxyl radicals by the photo-oxida-
tion of pheomelanin or by porphyrin are 
well established (Menon et al., 1983; 
Nordberg and Arner, 2001). The ques-
tion arises: how do these ROS affect 
protein structures?
In this context, the two amino acids 
methionine and tryptophan in protein 
sequences are targets for oxidation, con-
sequently leading to structural altera-
tions and thus deactivation of proteins 
(for review see Schallreuter, 2005). 
Methionine is more vulnerable to oxi-
dation by ROS than tryptophan; it forms 
two diastereomers of methionine sulf-
oxide (R and S), whereas tryptophan is 
converted to 5-OH-tryptophan (Neiers et 
al., 2004). It has been shown that several 
important enzymes are deactivated by 
hydrogen peroxide because of oxidation 
of those two amino acid residues in their 
sequences, including pterin 4a-carbi-
nolamine dehydratase (EC 4.2.1.96) and 
dihydropteridine reductase (EC 1.6.99.7), 
both involved in the recycling of the 
essential cofactor (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (6BH4), as well as 
acetylcholine esterase (EC 3.1.1.7) (for 
review see Schallreuter, 2005).
Maresca et al. identified 5-OH-tryp-
tophan and methionine sulfoxide as 
oxidation products of UVA/pheomela-
nin photo-oxidation in the sequence of 
catalase by applying fluorescence spec-
troscopy and micro-Raman spectros-
copy. The chosen reference standard 
for methionine sulfoxide has two peaks 
(see Figure 7 in Maresca et al., 2006), 
indicating that this standard must be a 
mixture of two compounds. One would 
suspect that the standard is a mixture of 
methionine sulfoxide and methionine 
sulfone, but this assumption should 
be confirmed by amino acid analysis 
(Hasse et al., 2004). Moreover, it is sur-
prising that the porphyrin ring of cata-
lase is not affected under the experi-
mental conditions chosen.
Computer-assisted analysis of the cat-
alase protein structure using HyperChem 
(Hyperchem Inc., Gainesville, FL, 
USA) and DeepView (Swiss Institute of 
Bioinformatics, Lausanne) indicates a 
significant change in the three-dimen-
sional structure of catalase after oxida-
tion of the eight methionine (at posi-
tions 61, 181, 212, 284, 339, 350, 392, 
and 394) and five tryptophan residues 
(at positions 143, 183, 186, 227, and 
303) in the sequence of each subunit. 
Taking into consideration that each 
methionine and each tryptophan gain 
one oxygen atom upon oxidation, it 
can be calculated that the molecular 
weight of one oxidized catalase sub-
unit would increase by 208 daltons. As 
the fully active enzyme is assembled by 
four subunits, the net gain would give 
a molecular weight of 1.232 kilodal-
tons, consequently changing the tertiary 
structure with partial deletion of some 
α-helices and some β-pleated sheets, 
which in turn would alter the isoelec-
tric point, explaining the results of the 
Western blot in the report by Maresca et 
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